HEMLIBRA (emicizumab-kxwh)

OFFICE OR HOME HEALTH ADMINISTRATION

Indications for Prior Authorization:

  • Indicated for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors

Patients must meet the following criteria for the indication above:

  • Diagnosis of hemophilia A (congenital factor VIII deficiency), AND
  • Prescribed by or in consultation with a hemophilia specialist, AND
  • The patient has factor VIII inhibitors

Dosing:

  • Loading dose: 3 mg/kg by subcutaneous injection once weekly for the first 4 weeks
  • Maintenance dose:
    • 1.5 mg/kg once every week, OR
    • 3 mg/kg once every two weeks, OR
    • 6 mg/kg once every four weeks
  • Discontinue the prophylactic use of bypassing agents the day before starting Hemlibra prophylaxis
  • The prophylactic use of factor VIII (FVIII) products may be continued during the first week of Hemlibra prophylaxis

Approval:

  • 1 year

Last review date: December 17, 2018

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone